In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
Vishal N. Rao(Duke University), Stephen J. Greene(Duke Medical Center), Jennifer B. Green, Javed Butler(Jackson Memorial Hospital), Kavita Sharma(Johns Hopkins University), Zachary L. Cox(Vanderbilt University Medical Center), Mona Fiuzat(Duke University), Cara O’Brien(Duke University), Muthiah Vaduganathan(Brigham and Women's Hospital), Robert J. Mentz(Duke University), Gregg C. Fonarow(UCLA Medical Center), Darren K. McGuire(Parkland Health & Hospital System), Evan Murray(Duke University), Lauren B. Cooper, Michael E. Nassif(Saint Luke's Health System), Neha J. Pagidipati(Duke University), JoAnn Lindenfeld(Vanderbilt University Medical Center), Orly Vardeny(University of Minnesota)
Cited by 93
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k